Zhao, Shui-Ping

HDL and ApoA-I inhibit antigen presentation-mediated T cell activation by disrupting lipid rafts in antigen presenting cells

Wang, S.-H., Yuan, S.-G., Peng, D.-Q., & Zhao, S.-P. (2012) · Atherosclerosis

Cholesterol and Lipid MetabolismAtherosclerosis and Cardiovascular Diseases

Cited by 111

Effects of Xuezhikang in patients with dyslipidemia: a multicenter, randomized, placebo-controlled study

Moriarty, P. M., Roth, E. M., Karns, A., Ye, P., Zhao, S.-P., Liao, Y., Capuzzi, D. M., Bays, H. E., Zhang, F., Liu, S., et al. (2014) · Journal of clinical lipidology

Lipoproteins and Cardiovascular HealthNatural Products and Biological Research

Cited by 65

Atorvastatin and fenofibrate increase apolipoprotein AV and decrease triglycerides by up‐regulating peroxisome proliferator‐activated receptor‐α

Huang, X., Zhao, S., Bai, L., Hu, M., Zhao, W., & Zhang, Q. (2009) · British Journal of Pharmacology

Lipid metabolism and disordersPeroxisome Proliferator-Activated Receptors

Cited by 36

Plasma lipoproteins in familial dysbetalipoproteinemia associated with apolipoproteins E2(Arg158-->Cys), E3-Leiden, and E2(Lys146-->Gln), and effects of treatment with simvastatin.

Zhao, S. P., Smelt, A. H., Van den Maagdenberg, A. M., Van Tol, A., Vroom, T. F., Gevers Leuven, J. A., Frants, R. R., Havekes, L. M., Van der Laarse, A., & Van 't Hooft, F. M. (1994) · Arteriosclerosis and Thrombosis: A Journal of Vascular Biology

Lipoproteins and Cardiovascular HealthLipid metabolism and disorders

Cited by 22

Lipoprotein profiles in a family with two mutants of apolipoprotein E: Possible association with hypertriglyceridaemia but not with dysbetalipoproteinaemia

Zhao, S.-P., Van den Maagdenberg, A. M. J. M., Vroom, T. F. F. P., Hooft, F. M. V., Leuven, J. A. G., Havekes, L. M., Frants, R. R., Van Der Laarse, A., & Smelt, A. H. M. (1994) · Clinical Science

Lipid metabolism and disordersLipoproteins and Cardiovascular Health

Cited by 9